Jefferson Moss-Magee Rehabilitation - Elkins Park
Elkins Park, Pennsylvania, 19027, United States
NCT Number: NCT06247904
No accepted clinical therapies exist for repair of motor pathways following spinal cord injury (SCI) in humans, leaving permanent disability and devastating personal and socioeconomic cost. A robust neural repair strategy has been demonstrated in preclinical studies, that is ready for translation to recovery of hand and arm function in human SCI, comprising daily transcranial magnetic stimulation treatment at the inpatient rehabilitation facility. This study will establish clinical effect size of the intervention, as well as safety and feasibility necessary for a subsequent controlled efficacy trial and inform preclinical studies for dosing optimization.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Elkins Park, Pennsylvania, 19027, United States
The objective of this proposal is to begin translating findings from pre-clinical studies to human motor deficits following cervical SCI (cervSCI). This HF-rTMS treatment protocol has not been previously assessed in human SCI and is qualitatively different from rTMS protocols reported to transiently modulate excitability of existing pathways, previously demonstrated in the literature. The protocol involves a daily stimulation of ~10 mins bilateral HF-rTMS for 2 weeks. SCI participants will be studied in a United States inpatient setting for this phase I study.
Given the findings in the pre-clinical model of robust axonal sprouting and functional synapse formation close to the damaged tissue using the above stimulation parameters, the transcranial magnetic stimulation treatment will target the hand-forearm region of the primary motor cortex, bilaterally. The aim is to include the cortical representation of affected muscles adjacent to the neurological level of injury. This zone often contains a mix of clinically and neurophysiologically intact, weakly innervated and denervated corticospinal pathways. Under standard sub-acute rehabilitation care, recovery of up to 1 neurological level of injury (NLI) is often the case, but improvement of 2 or more levels is far less common (<30% of patients). To examine the feasibility and safety of this novel intervention is the principal aim of the study. The associated potential clinical and neurophysiological changes will also be evaluated. These preliminary data will be used to power a subsequent efficacy trial to test the hypothesis that rTMS induced corticospinal augmentation will result in greater than typical extension of the NLI in human SCI, assessed up to the stable recovery phase at 6 months post-injury.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.
Other names: active repetitive transcranial magnetic stimulation
The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
Other names: sham repetitive transcranial magnetic stimulation
Time frame: 21 months (Recruitment period)
The proportion of patients who can take part in the study, whether they later agree to or not.
Time frame: 21 months (Recruitment period)
The proportion of eligible patients who agree to take part in the study.
Time frame: 2 years (Duration of human subjects' involvement)
Proportion of intervention-related dropouts.
Time frame: 2 years (Duration of human subjects' involvement)
Proportion of patients that complete the assessments at the start and the end of the intervention.
Time frame: 2 years (Duration of human subjects' involvement)
The number of patients who drop out or were 'lost' at the 6-month follow-up.
Time frame: 2 years (Duration of human subjects' involvement)
Rate of adverse and serious adverse events
Time frame: Baseline and 6 months after injury
Proportion of patients with Improvement of 2 or more motor zone of partial preservation levels from baseline to 6 months after injury.
Time frame: Baseline and 6 months after injury
The proportion of re-connectivity will be estimated by treatment group.
Time frame: Baseline and 6 months after injury
Change in motor threshold of key muscles will be estimated bilaterally within each group and a comparison of the change between groups.
Albert Einstein Healthcare Network
Other
Noninvasive Brain Stimulation Therapy in Subacute Human Spinal Cord Injury: A Translational Study
Acronym: NIBS-SCI1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07625332
Central Nervous System Diseases, Glucose Metabolism Disorders
West Orange, New Jersey, United States
View Trial DetailsNCT00913471
Central Nervous System Diseases, Nervous System Diseases
Houston, Texas, United States
View Trial DetailsNCT06463418
Central Nervous System Diseases, Nervous System Diseases
Dublin, Ireland
View Trial DetailsNCT05869968
COVID-19 Vaccine, Central Nervous System Diseases
Manhasset, New York, United States
View Trial Details